We are live on ! Find out more
ProShare Advisors

ProShare Advisors Portfolio holdings

AUM $67.5B
1-Year Est. Return 28.09%
This Fund
S&P 500
This Quarter Est. Return
-4.85%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$46.6B
AUM Growth
-$4.41B
Cap. Flow
-$915M
Cap. Flow %
-1.97%
Top 10 Hldgs %
31.78%
Holding
2,365
New
27
Increased
297
Reduced
1,868
Closed
169

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$170M
2
T icon
AT&T
T
+$142M
3
MSFT icon
Microsoft
MSFT
+$136M
4
XLNX
Xilinx Inc
XLNX
+$110M
5
AMZN icon
Amazon
AMZN
+$86.9M

Sector Composition

Rank Sector Weight
1 Technology 31.53%
2 Consumer Discretionary 13.24%
3 Communication Services 9.89%
4 Healthcare 9.39%
5 Consumer Staples 8.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
QTTB icon
2126
Q32 Bio
QTTB
$450M
$42K ﹤0.01%
765
-191
-20% -$11.9K
TCRT icon
2127
Alaunos Therapeutics
TCRT
$4.74M
$41K ﹤0.01%
411
-97
-19% -$12.4K
TK icon
2128
Teekay
TK
$975M
$41K ﹤0.01%
13,020
-2,153
-14% -$6.97K
SCOR icon
2129
Comscore
SCOR
$110M
$39K ﹤0.01%
656
-109
-14% -$6.25K
VKTX icon
2130
Viking Therapeutics
VKTX
$4.04B
$39K ﹤0.01%
12,825
-2,122
-14% -$7.61K
OTLK icon
2131
Outlook Therapeutics
OTLK
$263M
$38K ﹤0.01%
1,068
+95
+10% +$2.97K
PASG icon
2132
Passage Bio
PASG
$15.9M
$38K ﹤0.01%
628
-158
-20% -$13K
ADMA icon
2133
ADMA Biologics
ADMA
$1.92B
$37K ﹤0.01%
20,265
-7,311
-27% -$11.4K
SMMT icon
2134
Summit Therapeutics
SMMT
$10.9B
$37K ﹤0.01%
15,054
-4,464
-23% -$11.3K
EVLO
2135
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$37K ﹤0.01%
561
-147
-21% -$12.2K
VLDR
2136
DELISTED
Velodyne Lidar, Inc. Common Stock
VLDR
$37K ﹤0.01%
14,351
-2,160
-13% -$7.39K
AKBA icon
2137
Akebia Therapeutics
AKBA
$327M
$36K ﹤0.01%
50,807
-11,934
-19% -$25.5K
LCTX icon
2138
Lineage Cell Therapeutics
LCTX
$257M
$36K ﹤0.01%
23,513
-3,884
-14% -$6.03K
RNAC icon
2139
Cartesian Therapeutics
RNAC
$232M
$36K ﹤0.01%
978
-240
-20% -$15K
XERS icon
2140
Xeris Biopharma Holdings
XERS
$1.44B
$36K ﹤0.01%
13,983
-3,578
-20% -$8.74K
ADVM
2141
DELISTED
Adverum Biotechnologies
ADVM
$34K ﹤0.01%
2,644
-636
-19% -$9.31K
CARM
2142
DELISTED
Carisma Therapeutics
CARM
$34K ﹤0.01%
2,919
-684
-19% -$9.55K
DNTH icon
2143
Dianthus Therapeutics
DNTH
$5.68B
$34K ﹤0.01%
731
-195
-21% -$10.7K
VIEW
2144
DELISTED
View, Inc. Class A Common Stock
VIEW
$34K ﹤0.01%
307
-200
-39% -$30.2K
TLMD
2145
DELISTED
SOC Telemed, Inc. Class A Common Stock
TLMD
$34K ﹤0.01%
11,385
-1,884
-14% -$4.15K
TNXP icon
2146
Tonix Pharmaceuticals
TNXP
$157M
0
SURF
2147
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$33K ﹤0.01%
11,399
-2,817
-20% -$9.87K
KG
2148
Kestrel Group
KG
$71.3M
$32K ﹤0.01%
652
-107
-14% -$5.63K
IMDX
2149
Insight Molecular Diagnostics
IMDX
$153M
$31K ﹤0.01%
1,041
-266
-20% -$8.51K
ADAP
2150
DELISTED
Adaptimmune Therapeutics
ADAP
$29K ﹤0.01%
14,203
-5,112
-26% -$13.8K

Similar funds

ProShare Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, ProShare Advisors held 2,365 positions worth $46.6B, down 8.6% from $51B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

ProShare Advisors's Q1 2022 filing shows 27 new, 297 increased, 1,868 reduced and 169 closed positions. Its largest new stake was Constellation Energy: 594,655 shares worth $33.4M. The largest sale was Apple, an estimated $170M.

By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 33% a quarter earlier, followed by Consumer Discretionary and Communication Services.

  • ProShare Advisors's largest Q1 2022 buy was Constellation Energy: 594,655 shares worth $33.4M.
  • ProShare Advisors added most to Brown & Brown in Q1 2022, an estimated $161M increase.
  • ProShare Advisors's biggest Q1 2022 reduction was Apple, cutting an estimated $170M.
  • ProShare Advisors fully exited Xilinx Inc in Q1 2022, selling an estimated $110M.
  • ProShare Advisors's ten largest holdings make up 32% of its $46.6B portfolio in Q1 2022.
  • ProShare Advisors opened 27 new positions and closed 169 in Q1 2022.
  • ProShare Advisors's portfolio value fell 8.6% quarter-over-quarter to $46.6B.

Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.